Counterfeit Botox and the Accountability Gap: My Op-Ed on an Industry That Still Isn't Watching Closely Enough

This week two regulatory developments landed within days of each other: the UK's MHRA sharpened its warning language around iatrogenic botulism from botulinum-toxin products, and Canadian and international authorities seized a batch of unauthorized, counterfeit injectables sold online. Read separately, they look like routine regulatory housekeeping. Read together, they describe the same unresolved problem: this industry still asks patients to trust a supply chain and a credentialing system that, in practice, is largely invisible to them.

The warning update matters more than its headline suggests

The MHRA's update clarifies which symptoms belong on the urgent-care ladder: progressive weakness, and difficulty breathing, swallowing, or speaking. That is useful, overdue clarity for patients. But as a prescribing physician, my read is less about the symptom list and more about why the warning needed updating at all. Iatrogenic botulism from cosmetic treatment is rare specifically because the approved products, handled through a legitimate chain of custody and injected by a trained clinician at labeled or medically justified doses, are engineered to stay local. When that chain breaks — counterfeit product, unverified sourcing, unsupervised injection, doses that are effectively guesswork — the rare complication becomes less rare.

Counterfeit product is not a fringe problem

The seizure of unauthorized injectable products sold online is not an isolated event; it is a recurring pattern that the FDA, Health Canada, and other regulators have flagged repeatedly over the past several years. What strikes me is how little friction exists between a counterfeit seller and a patient's face. A slick storefront, a discounted price, and a willingness to skip the question of where the product actually came from are often all it takes. Patients rarely ask to see a lot number. Many practices do not volunteer one.

I think this is where the industry has failed to police itself. Product authenticity should not be a differentiator that only conscientious practices bother to mention — it should be a baseline disclosure, stated plainly, every time. The fact that it still functions as a selling point rather than a standard tells you how uneven enforcement has been.

Where I place the responsibility

I do not think the answer is to frighten patients away from a medication with a genuinely strong safety record when used correctly. The answer is to stop treating sourcing and credentialing as optional context. A practice that cannot state, without hesitation, the exact product name, its authorized distributor, and the training and licensure of the injecting clinician has not earned the trust it is asking for. That standard should not depend on a patient knowing to ask. It should be disclosed before the question is necessary.

Regulators can seize counterfeit shipments after the fact. They cannot be in the room during a consultation. That accountability sits with the clinician, and with an industry that has been slow to make transparency the default rather than the exception.

What I would ask this industry to change

Make product and sourcing disclosure a spoken, standard part of every consultation — not a detail buried in consent paperwork. Stop pricing structures that reward speed over verification. And treat a patient's question about product authenticity as a normal, expected part of the visit, not an inconvenience. None of this requires new legislation. It requires practices to hold themselves, and each other, to a standard the regulators are only now catching up to describe.

Readers who want the practical, patient-facing version of this — what to ask before treatment and which symptoms warrant urgent care — can find it in my companion article on Botox side effects and red flags. This piece is the harder question underneath it: why patients still have to ask at all.

— Dr. Iryna Lazuk, MD, Lazuk Esthetics, Alpharetta, Georgia